Modulari-T has developed a 2nd Generation In Vivo approach that unlocks new avenues in In Vivo Cell and Gene Therapy (CGT), by combining novel receptors and delivery vehicles that were developed from the in-depth understanding of the natural modulatory and power of native Immune receptors.
What is the problem?
The current in vivo CAR-T field is limited to old, repurposed, off-the-shelf ex vivo technology for both constructs and delivery leading to poor targeting, potency, and limited use. CAR-T therapies have demonstrated significant benefit for a subset of patients with B-Cell leukemias and lymphomas.
What is their solution?
Modulari-T has developed a 2nd Generation In Vivo approach that unlocks new avenues in In Vivo Cell and Gene Therapy (CGT), by combining novel receptors and delivery vehicles that were developed from the in-depth understanding of the natural modulatory and power of native Immune receptors. Using our protein design engine, we have created a platform that enables the development of 2nd generation in vivo CGT by removing restriction to T cells to enable other immune cells, expanding efficacy with bi-specific approaches and targeting precision, decreasing off-target effects to potentiate in vivo transduction, and lastly, generating novel constructs that can target low pH and retain specific and efficacy in low expression targets.
